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Significant evidence has accumulated that DNA-methylation of the paired-like homeodomain 
transcription factor 2 (PITX2) gene can serve as a prognostic and predictive biomarker in breast cancer. 
PITX2 DNA-methylation data have been obtained so far from microarray and polymerase chain reaction 
(PCR)-based research tests. The availability of an analytically validated in vitro methylation-specific 
real-time PCR assay format (therascreen PITX2 RGQ PCR assay) intended for the determination of 
the percent methylation ratio (PMR) in the (PITX2) promoter 2 prompted us to investigate whether 
the clinical performance of these different assay systems generate comparable clinical outcome 
data. Mathematically converted microarray data of a previous breast cancer study (n = 204) into 
PMR values leads to a PITX2 cut-off value at PMR 14.73. Recalculation of the data to experimentally 
equivalent PMRs with the PCR PITX2 assay leads to a cut-off value at PMR 12 with the highest statistical 
significance. This cut-off predicts outcome of high-risk breast cancer patients to adjuvant anthracycline-
based chemotherapy (n = 204; Hazard Ratio 2.48; p < 0.001) comparable to microarray generated 
results (n = 204; Hazard ratio 2.32; p < 0.0001). The therascreen PITX2 RGQ PCR assay is an analytically 
validated test with high reliability and robustness and predicts outcome of high-risk breast cancer 
patients to anthracycline-based chemotherapy.
Breast cancer is the most common malignancy in women with >464,000 new cases diagnosed in 2012 in Europe1. 
The St. Gallen classification includes steroid hormone receptor status and human epithelial growth factor receptor 
2 (HER2) status, nodal status, tumor size and other clinicopathological factors to classify low- (10%), medium- 
(65%) and high-risk (25%) patient groups and help to guide therapy decision2,3. These prognostic factors provide 
information about the future clinical course of the disease e.g. disease-free survival (DFS) and overall survival 
(OS) of patients not subjected to any systemic cancer therapy. Different from that, predictive factors assess the 
probability of a cancer patient to respond and to benefit to a specific anti-cancer therapy. Those predictive bio-
markers (proteins) are for example estrogen receptor (ER) and progesterone receptor (PR), the HER2 (human 
epithelial growth factor receptor 2) receptor, and the urokinase-type plasminogen activator (uPA) and its inhib-
itor PAI-1 (ASCO - American Society of Clinical Oncology: http://asco.org/practice-guidelines). ER and PR 
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receptor status are usually assayed by immunohistochemistry (IHC), HER2 by IHC or by Fluorescence In-Situ 
Hybridization (FISH) or uPA/PAI by enzyme linked immunosorbent assay (ELISA).
Tumors classified as high-risk cancer with poor prognosis include triple-negative and HER2 positive breast 
cancer, patients with lymph node involvement4 and patients classified through multigene mRNA signatures such 
as Endopredict® (Myriad Genetics Inc., Salt Lake City, Utah, USA), OncotypeDX® (Genomic Health, Redwood 
City, CA, USA) or Mammaprint® (Agendia Inc., Irvine, CA, USA) to be at high risk to develop metastasis5,6. 
Standard of care treatment of those high-risk breast cancer patients is an anthracycline-based chemotherapy. In 
addition, an adjuvant endocrine therapy will be administered if tumor cells are ER and/or PR positive. However, 
not all patients respond to anthracycline-based chemotherapy, and part of the patients suffer from side-effects 
without any benefit. Until now biomarkers to predict outcome to anthracycline-based chemotherapy are of high 
unmet medical need.
DNA-methylation of the PITX2 (paired-like homeodomain transcription factor 2) gene as a predictive and 
prognostic biomarker for patient selection has received increasing attention not only in breast cancer7–9. PITX2 
is a transcription factor, which is involved in pituitary-specific gene regulation and left-right patterning dur-
ing embryonic and organogenic development9. It has been shown that DNA-methylation of the PITX2 pro-
moter gene predicts risk of distant metastasis in node-negative, hormone receptor-positive breast cancer10–12. 
Significant evidence has accumulated that PITX2 methylation predicts outcome in lymph node-positive, ER 
positive, HER2 negative breast cancer patients to adjuvant anthracycline-based chemotherapy and, thus, will 
support the clinicians to the most effective therapy option13,14. In these studies, different technological platforms 
for DNA-methylation analysis were used and performed on different types of tissue specimens. Those studies 
include a proprietary microarray platform developed by the company Epigenomics AG (Berlin, Germany) for 
on DNA methylation based biomarker screening using bisulfite converted DNA (bisDNA) specific probes for 
the methylated and unmethylated status of CpG residues11,13 or a ‘research use only’ (RUO) real-time PCR assay 
covering three of the most relevant CpG residues for clinical response prediction in tamoxifen treated breast 
cancer patients11.
Recently, we developed an analytically validated PITX2 DNA-methylation assay (therascreen PITX2 RGQ 
PCR15, which is by now CE-marked and commercially available9. Here we describe results of the technical eval-
uation study of the therascreen PITX2 RGQ PCR assay according to Clinical and Laboratory Standards Institute 
(Clinical and Laboratory Standards Institute - CLSI; https://clsi.org/) guidelines for lymph node positive, ER pos-
itive, HER2 negative breast cancers. The therascreen PITX2 assay is deployable for routine diagnostic setting and 
the determined PMR value will aid clinicians to identify patients who are more versus less likely to benefit from 
adjuvant anthracycline-based chemotherapy. The goal of the present study was to investigate whether the clini-
cal relevance of PITX2 DNA-methylation determined by the novel therascreen PITX2 DNA-methylation assay 
delivers the same results compared to the previously applied microarray technology13 and research PCR assay11.
Material and Methods
Sample preparation, DNA extraction and bisulfite conversion. Sample preparation from Fresh-
Frozen (FF) tumor tissue: after surgical removal, breast tumor tissues were placed immediately on ice until exam-
ination by the pathologist. Thereafter, tissue was snap-frozen and stored in liquid nitrogen until further use. FF 
tumor tissue was processed to tumor cell nuclei pelleted at 100,000 × g at Erasmus Medical Center, Rotterdam 
as described13,16. Samples were transferred to Therawis Diagnostics GmbH, Munich. Genomic DNA (gDNA) 
was extracted from 10–30 mg FF tumor cell nuclei pellets using the QIAamp® DNA Mini Kit (QIAGEN, Hilden, 
Germany; Catalog No.: 51304/51306).
Formalin-fixed paraffin-embedded (FFPE) tumor tissue samples were prepared by fixation for 12–24 hrs in 
10% neutral buffered formalin and embedded in paraffin. Tissue blocks were stored at room temperature and 
archived at the Institute of Pathology, Klinikum rechts der Isar, Technische Universität München until further 
use. gDNA was purified from one to two 5 µm FFPE tissue sections with a total surface area ≥100 mm2 using the 
QIAamp DNA DSP FFPE kit (Qiagen, Hilden, Germany; Catalog No.: 60404).
DNA quantification was performed with the QIAxpert spectrophotometer (Qiagen, Hilden, Germany) using 
the QIAamp DNA plugin with internal blank calibration for elution buffer ATE with the OD260 readout of total 
nucleic acids. DNA bisulfite conversion of the gDNA was performed using the Epitect Fast DNA Bisulfite Kit 
(Qiagen, Hilden, Germany, Catalog No.: 59824/59826) using 200–1000 ng input into the bisulfite conversion 
according to the therascreen PITX2 RGQ PCR Kit workflow15. This equals a bisDNA input in the qPCR into 
quantitative PCR (qPCR) of 53–267 ng bisDNA/well. All samples are measured in duplicates.
Methylation-specific custom microarray. A customized methylation-specific oligonucleotide array was 
developed by Epigenomics AG for 61 genes for initial screening in a population of 384 breast cancer samples13. 
CpG sites from regulatory regions of the candidate genes were amplified in multiplex PCR reactions labeled with 
the fluorochrome Cy5 from bisulfite-treated genomic DNA with bisulfite-converted DNA specific primer pairs. 
In total, 64 PCR amplificants representing 61 genes were pooled and hybridized to the microarray on which 
detection oligonucleotides for methylated (CG) and nonmethylated (TG) gene copies were spotted. This allowed 
for simultaneous quantitative measurement of unmethylated and methylated copies of the genes. Microarrays 
included 4 oligonucleotide pairs for each of the 64 PCR amplificates (total of 256 pairs). Each probe pair covered 
between one and three CpG dinucleotides in the regulatory regions of the respective candidate gene. The methyl-
ation score for each CpG site was calculated from the fluorescence intensity values of the methylated (=FIm) and 
unmethylated (=FIu) oligonucleotides. To stabilize the variance, the score was transformed using the generalized 
log transformation (gLOG): methylation score = gLOG(FIm/FIu)17. For statistical analysis, methylation scores 
for each amplificate were determined by averaging measurements from all probe pairs belonging to one amplifi-
cate using the median. Multiple amplificates from the same candidate gene entered data analysis independently. 
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According to Maier et al. (shown in Fig. 1) 3 CpGs with the most relevant clinical impact were selected from the 
PITX2 promoter 2 gene (PITX2P2; 4q25) region on the respective custom array, which were represented by two 
of the four probe pairs11. These 3 CpGs are covered by the Taqman probes of the therascreen PITX2 RGQ assay.
therascreen PITX2 RGQ PCR assay. The therascreen PITX2 RGQ PCR Kit (QIAGEN, Catalog no. 
873211) is a real-time DNA-methylation-specific PCR-based assay (qMSP) and exploits the quantitative PCR 
(qPCR) oligonucleotide hydrolysis principle of two TaqMan probes (labelled with fluorescent dye FAMTM for fully 
methylated and HEXTM for fully unmethylated probe) in combination with methylation-unspecific primers. The 
sample type is bisDNA, i.e., bisulfite converted genomic DNA (gDNA). This assay uses one pair of primers ampli-
fying all bisulfite-converted target sequences of the PITX2 gene promoter 2 by its methylation specific probes15. 
PITX2-probe and primer system specifications: Entrez gene ID: 5308. Amplicon length 144. Reference sequence 
(Ref Seq) ID: NT_016354.18 (4q25. Detected CpG in Ref Seq: 3 CpG in 36106573–3610660011. After bisulfite 
exposure to distinguish between methylated and unmethylated PITX2, the percent methylation ration (PMR) 
of three CpG motifs of the PITX2 gene promoter 2 is quantified by qMSP and calculated by the Rotor-Gene 
AssayManager® software with Gamma Plug-in plus a kit-specific PITX2 Assay Profile for automated analysis 
and quality control including all validity criteria. Validity criteria for run controls and sample testing include 
cycle threshold (Ct), amplification curve anomalies, PMR range for the controls (PITX2 RGQ PCR reference 50, 
PITX2 RGQ PCR reference low, PITX2 RGQ PCR negative control (NC), PITX2 RGQ PCR NTC (NTC)) and 
delta-PMR threshold for sample duplicates as described in detail in the handbook18.
The PMR (percent methylation ratio) is calculated applying the following formula: PMR = 100/(1 + 2exp(Ct-
FAM(methylated) − CtHEX(unmethylated))]15. The PITX2 qMSP assay was optimized for the usage as an in vitro diagnostic 
assay following the CLSI guidelines (https://clsi.org/; see also18). PCR analysis is performed on Rotor-Gene Q 
MDx 5plex HRM instrument (Qiagen, Hilden, Germany).
Patients and tumor samples. For the analytical and technical evaluation of the therascreen PITX2 
RGQ PCR assay, Formalin-Fixed Paraffin-Embedded (FFPE) tumor tissue samples from invasive breast can-
cers (n = 131; thereof 61 ER+ and 68 ER−) were collected at the Institute of Pathology, Technische Universität 
München. From these cases incomplete clinical and follow-up data were available. Therefore, the FFPE samples 
were only used to optimize the workflow, perform the analytical and technical evaluation including determina-
tion of DNA extraction yields, pass rates (run pass rate and sample pass rate), and tumor heterogeneity.
For the establishment of the transformation curve with the therascreen PITX2 RGQ PCR assay, Fresh frozen 
(FF) tumor tissue samples (n = 121) processed to tumor cell nuclei pellets were provided by the Erasmus Medical 
Center (EMC), Rotterdam, The Netherlands.
From a study published by Hartmann et al. 2009, 384 patients were evaluated according to the following 
eligibility criteria: invasive breast cancer, tumor stage pT1 to pT3, histologically confirmed lymph node involve-
ment (>pN1), availability of clinical follow-up data of at least 5 years, availability of PITX2 methylation-specific 
microarray data, and, finally, standard adjuvant anthracycline-based chemotherapy (no dose-dense therapy, no 
other primary systemic chemotherapy, except hormonal therapy, and no additional taxanes) (Fig. 1).
Figure 1. Consort diagram with samples for clinical evaluation of therascreen PITX2 RGQ PCR assay. ER - 
Estrogen receptor; HER2 - human epithelial growth factor receptor 2; LN - lymph node; FF - fresh-frozen.
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From 121 of the 384 patients (Fig. 1), both fresh-frozen tumor tissue specimens and microarray data of PITX2 
DNA methylation were available, but not all samples met the inclusion criteria of the clinical study population 
Also, the available clinical data of this group of 121 patients were partly incomplete and, therefore, could not be 
used for outcome analysis. The 121 samples, which were collected at the Erasmus Medical Center in Rotterdam 
were used to analyze the correlation between mathematically converted microarray gLOG (FIm/FIu) data to 
PMR values [PMRcalc = 2exp(gLOG (FIm/FIu))] and their respective PMR values experimentally (PMRexp) deter-
mined with the therascreen PITX2 RGQ PCR assay according to the formula: PMRexp = 100/[1 + 2exp(CtFAM(meth-
ylated) − CtHEX(unmethylated))] from fresh frozen tumor tissue samples.
204 patients (ER positive, HER2 negative) of the 384 patients were selected for the clinical validation study 
group (Fig. 1). This clinical validation study group was considered for determination of PITX2 cut-off points and 
to perform Kaplan-Maier analyses by using available microarray gLOG (Flm/Flu) data from fresh-frozen tissue 
samples transformed into PMR values by a) mathematically calculation (PMRcalc) and b) applying the established 
transformation curve to calculate therascreen PITX2 RGQ PCR assay equivalent PMR data (PMRequiv) and using 
the clinical data of this group (Fig. 1 – bold box). The histopathological and clinical criteria of this group are 
summarized in Table 1.
Experimental studies involving human tissue material. Any experiments on human tissue material 
cited which were conducted in cooperation with the Department of Obstetrics and Gynecology (Frauenklinik) 
and the Institute of Pathology of the Technische Universität München, Munich, Germany, and with Erasmus 
Medical Center, Rotterdam, The Netherlands, were done in accordance with the Declaration of Helsinki (1964) 
and in accordance to the Code of Conduct of the Federation of Medical Scientific Societies in the Netherlands 
(www.federa.org/codes-conduct). The laboratory experiments were performed with the human subjects’ under-
standing, who provided written informed consent for using the respective tissue specimens. The present study 
was approved by the local Ethical Committee of the Technische Universität München – Faculty of Medicine, 
Munich, Germany.
Statistical methods. Fractional polynomial approach was used to analyze the correlation between PMR 
data calculated from gLOG values of methylation-specific microarray data (PMRcalc) and PMR data measured 
with the therascreen PITX2 RGQ assay (PMRexp) values to determine the best-fitting function19. gLog(2) flu-
orescence intensity values (gLOG Flm/Flu)) of PITX2 on a methylation specific oligonucleotide microarray20 
were transformed into PMR values (PMRcalc) by the formula: PMRcalc = 2exp(gLOG) to allow for comparabil-
ity with PMR data (PMRexp) from the therascreen PITX2 RGQ PCR assay according to the respective probe 
Clinical characteristics n (%)
No. cases 204 (100)
Age at time of diagnosis
<50 years 90 (44)
≥50 years 114 (56)
Tumor stage (pT)
T1 74 (36)
T2, T3, T4 128 (114; 14; 0) (63)
TX (unknown) 2 (1)
Involved lymph nodes
1–3 110 (54)
>3 94 (46)
ER status
positive 204 (100)
HER2/neu status
negative 204 (100)
Therapy
Anthracycline-based plus endocrine therapy 96 (47)
Anthracycline-based without endocrine therapy* 108 (53)
Disease recurrence
Yes 94 (46)
No 110 (54)
Overall survival (event)
Yes 46 (23)
No 158 (77)
Table 1. Clinical Study Population. Clinical and histopathological characteristics of patients (n = 204). *With 
the ASCO/CAP (American College of Pathology) recommendation in 2010, a consensus threshold reporting ER 
as positive was set at 1%32. Consequently, prior to the change of guidelines, patients with low level ER expression 
(between 1% and 10%) were not necessarily treated with endocrine therapy.
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CT read-outs [PMRexp = 100/(1 + 2exp(CtFAM(methylated) − CtHEX(unmethylated)))]. The resulting polynomial regres-
sion analysis function [PMRequiv = 12.12773 + 11.61198*((2exp(gLOG)/10*100) − 1.491) − 0.0938867*((2exp(
gLOG)/10*100)3 − 3.314))] was used to mathematically calculate PMRcalc values into therascreen PITX2 RGQ 
assay equivalent PMR values (PMRequiv) sample by sample from the Clinical Study Population (n = 204; Fig. 1).
Disease-free survival (DFS) was the primary endpoint and defined as the time from primary surgery to the first 
documented event, which includes any of the following: local recurrence of disease (n = 19) or distant metastasis 
(n = 70) or contralateral breast cancer (n = 5). Analysis was performed for DFS follow-up time of 120 months. 
The PITX2 cut-off value for disease-free survival (DFS) was established with the “maximum-selected log-rank 
statistics” using the maxstat.test function as implemented by the program library “maxstat” of the program “R” (R 
Development Core Team 2012)21. The PITX2 cut-off value is the Percentage Methylation Ratio (PMR) of PITX2 
which separates good survivors and poor survivors (responder vs. non-responder) by using the log-rank statistics 
algorithm (R Software version: R version 3.4.1, 2017; the R Foundation for Statistical Computing).
Results
Assay performance. The verification data and the analytical validity of the therascreen PITX2 RGQ PCR 
DNA-methylation assay including limit of blank (PMR 0 for the methylated probe; PMR 98 for the unmethylated 
probe), limit of detection (PMR 4 for the lower limit; PMR 92 for the upper limit), repeatability and reproduci-
bility was tested with three biological samples (PMRs 7, 16, and 77) in a single-site precision study (variability for 
each sample = 20.39%, 21.76%, 4.23%, respectively; average of 15.46%) and multi-site precision study (variability 
for each sample = 16.93%, 28.72%, 4.61%, respectively; average of 16.75%) according to CLSI/NCCLS/EP5-A3 
guideline22, including intra-run variability (for each sample = 12.29%, 19.99%, 3.90%, respectively; average of 
12.06%) and inter-run variability (for each sample = 13.90%, 28.72%, 4.25%, respectively; average of 15.62%)15,18. 
Furthermore, interfering substances (8 substances; no biological impact on PMR results) according to CLSI/
NCCLS/EP7-A2 guideline23, cross-contamination (1.3%), and in-use timeframe (within 24 hours) were tested 
and described in detail15,18. The results showed that the therascreen PITX2 RGQ PCR DNA-methylation assay is 
reliable, robust and ready-to-use for routine diagnostics.
DNA yield from FFPE tumor sections. To verify the successful application of the therascreen workflow 
from FFPE material to PCR-based results, we used 131 FFPE breast cancer samples (63 estrogen receptor positive 
and 68 estrogen receptor negative), which were collected at the Institute of Pathology, Technische Universität 
München, as an independent cohort. From those samples, the genomic DNA (gDNA) was extracted from one to 
two 5 µm FFPE-tumor tissue sections with a total surface area ≥100 mm2. DNA quantification was performed 
with the QIAxpert spectrophotometer (Qiagen, Hilden, Germany) using the QIAamp DNA plugin with internal 
blank calibration for elution buffer ATE with the OD260 readout of total nucleic acids. For 110 tumor samples 
more than 400 ng of gDNA were obtained per sample, indicating an overall gDNA extraction pass rate of 84% for 
subsequent bisulfite conversion at the recommended gDNA input according to the assay format of 400 ng input 
(Table 2). The gDNA yield for the minimal gDNA input of 200 ng was achieved in 125 samples (95.4%). Samples 
with a tissue area below 100 mm2 (n = 5) had yields between 85 and 440 ng. In those cases, several pooled 5 µm 
sections for gDNA extraction were required.
Pass rates for qPCR runs and samples (DNA input). Six runs were performed to analyze 104 FFPE 
tissue tumor samples. The assays were performed with the recommended DNA input of 400 ng for bisulfite con-
version (n = 104) resulting in a final input of 106 ng bisulfite-converted DNA per well into qPCR. The six assay 
gDNA yield Samples
[ng] n (out of 131) [%]
<200 6 4.6
≥200 125 95.4
≥400 110 84.0
≥1000 79 60.3
Table 2. Genomic DNA (gDNA) extraction yields. Amount of gDNA from one 5 µm section and the respective 
tissue section areas. Total numbers of samples: 131. The input of 200–1000 ng gDNA into bisulfite conversion 
equals input of 53–267 ng bisDNA per well in the qPCR.
Total (n) Valid results Invalid results Rate [%]
Run pass rate - qPCR run performed 6 6 0 100
Sample pass rate - first-time 104 91 13 87.5
Sample pass rate - re-test 104 99 5 95.2
Table 3. Pass rates for qPCR runs and samples (DNA input). All criteria for run validity and sample DNA input 
validity were automatically applied according to the PITX2 Assay Profile of the therascreen PITX2 RGQ PCR 
Kit18. All determinations were performed in duplicates.
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Figure 2. Determination of PITX2 cut-off points and Kaplan Meier analysis. (a) Statistical analysis of PITX2 
cut-off points (PMR) for all patients (n = 204). Microarray gLOG data were converted with 2exp(gLOG) 
function to calculated PITX2 PMR data (PMRcalc); x-axis: Calculated PITX2 PMR data [%]; y-axis: Standardized 
log-rank statistics. Dashed vertical line marks the maximum cut-off point of PITX2 PMRcalc at 14.73. (b) 
Kaplan-Meier analysis for DFS of high-risk breast cancer patients (n = 204) using the maximum PITX2 cut-off 
point (PMRcalc = 14.73). Patients were treated with anthracycline-based chemotherapy ± endocrine therapy 
(HR 2.321; p < 0.001). Upper line: patients with PMR ≤ 14.73. Lower line: patients with PMR > 14.73. (c) 
Kaplan-Meier analysis for DFS of subgroup of high-risk breast cancer patients treated with anthracycline-
based chemotherapy and additional endocrine therapy (n = 96) using the maximum PITX2 cut-off point 
(PMRcalc = 14.73) (HR 2.285; p = 0.024). Upper line: patients with PMR ≤ 14.73. Lower line: patients with 
PMR > 14.73. (d) Statistical evaluation of PITX2 DNA percent methylation ratio (PMR) cut-off points. PMR 
data (n = 204) are equivalent (PMRequiv) to therascreen PITX2 RGQ PCR assay determined PMR values. 
x-axis: equivalent PITX2 PMR [%]; y-axis: Standardized log-rank statistics. The dashed vertical line marks the 
maximum log-rank statistic at a PITX2 PMR cut-off point of 12. (e) Kaplan-Meier analysis for DFS of high-risk 
breast cancer patients (n = 204) treated with anthracycline-based chemotherapy ± endocrine therapy using 
the optimized PITX2 cut-off point of PMRequiv = 12 (HR 2.478; p < 0.001). Upper line: PMR ≤ 12. Lower line: 
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runs performed were all valid (Table 3) according to the PITX2 Assay Profile for the therascreen PITX2 RGQ PCR 
Kit (see Materials and Methods).
The first-time sample pass rate was 87.5%. If invalid test results were obtained by the automated analysis soft-
ware of the PITX2 Assay Profile (see Materials and Methods), the qPCR run was repeated. According to the retest 
workflow of the therascreen PITX2 RGQ PCR Kit, a minimum of 200 ng gDNA up to 1000 ng gDNA input was 
used for bisulfite conversion. Upon retesting of 13 samples, the overall sample pass rate of valid results increased 
to 95.2%.
Tumor heterogeneity. To investigate the heterogeneity of PITX2 DNA-methylation within the same tumor 
sample, 5 consecutive tissue sections of the same tumor were analyzed. As denoted in Table 4, six analyzed tumor 
specimens gave coefficients of variations (CV) from 7.59% to 29.70%. However, the intra- and inter-assay varia-
bility range of the therascreen assay format is between 3.90–28.72%18. The variability range observed in consecu-
tive tumor sections with 7.59% to 29.70% is in the same range. Therefore, the contribution of tumor heterogeneity 
to PITX2 PMR value variability seems to be rather low.
Comparison of cut-off and clinical data derived from microarray analysis and therascreen PITX2 
RGQ PCR assay format. Hartmann et al. 2009 analyzed the performance of the PITX2 marker in 241 
ER-positive, HER2-negative, and lymph-node positive tumor tissue samples showing that PITX2 promoter 2 
(PITX2P2) hypermethylation was associated with a high risk of distant recurrence (time to distant metastasis) 
in the patient cohort (HR = 1.66; p = 0.002) and poor DFS (HR = 1.47; p = 0.0084) with the amplificate designed 
for the promoter of transcripts A and B of PITX2 (PITX2P2). The hazard ratio (HR) in this study was calculated 
relative to an increment from the lower quartile to the upper quartile13.
In order to examine if the clinical relevance (hazard ratio) are similar with data generated by microarray 
analysis or compared to data generated with the therascreen PITX2 assay for DFS the following strategy was 
pursued: 204 of 241 patient data were eligible (Fig. 1) and used for our analyses. The microarray data (gLOG data; 
Hartmann et al. 2009) from fresh frozen (FF) tissue of high-risk breast cancer patients (Fig. 1; n = 204) were con-
verted by mathematical calculation with 2exp(gLOG) function into PITX2 PMRcalc data and used to determine 
the best PITX2 cut-off value (PMRcalc) for DFS as shown in Fig. 2a. A pronounced single peak is shown reaching 
the highest statistical difference (z = 4.15) of two groups of patients with long and short DFS at a cut-off value of 
PMRcalc 14.73. Kaplan-Meier analysis applying the cut-off value of PMRcalc 14.73 identifies patients who benefit 
from anthracycline-based chemotherapy (n = 204; ±endocrine treatment) with a significant longer DFS (HR 
2.32, p < 0.0001) and those with less benefit from anthracycline-based chemotherapy (Fig. 2b).
PITX2 DNA-methylation also identifies patients in the group of breast cancer patients who received in addi-
tion to anthracycline-based chemotherapy endocrine therapy (n = 96) who have a significant longer DFS and 
those patients who have a significantly shorter DFS (HR 2.285, p = 0.024) (Fig. 2c). In order to confirm these 
results with a PCR-based analysis method we determined the PITX2 DNA-methylation applying the analytically 
validated therascreen PITX2 assay in 121 tumor cell nuclei pellets from fresh frozen (FF) tissue samples availa-
ble from the same study (Fig. 1). However, as the clinical data for these 121 samples were partly incomplete, we 
established a transformation curve with the PMR values derived from microarray (PMRcalc) and qPCR (PMRexp; 
assessed with the therascreen PITX2 RGQ PCR Kit) from these 121 samples. This resulted in a moderate corre-
lation coefficient factor of r = 0.722 (r-squared = 0.5219; n = 121) as shown in Fig. 3. The relative high number 
of zero values is due to the limit of detection of therascreen PITX2 RGQ PCR test which results in zero values for 
all PMRs between 0 and 4. The best fitting regression analysis function was determined by using the fractional 
polynomial approach (see statistical methods) and used to calculate PMRcalc values into therascreen PITX2 RGQ 
assay equivalent PMR values (PMRequiv) sample by sample from the Clinical Study Population (n = 204; Fig. 1).
The resulting therascreen PITX2 RGQ PCR assay equivalent PMR data (PMRequiv) were used to determine the 
best PITX2 cut-off value leading to PMRequiv = 12 for DFS as shown in Fig. 2d. The Kaplan-Meier curves with the 
applied cut-off value of PMRequiv = 12 identifies patients with improved survival after anthracycline-based chemo-
therapy (n = 204; ±endocrine treatment; HR 2.478; p < 0.001) (Fig. 2e) or anthracycline-based chemotherapy 
plus endocrine therapy (n = 96; HR 3.057; p = 0.002) (Fig. 2f).
The observed hazard ratios applying the cut-off derived from converted microarray data with PMRcalc = 14.73 
and from therascreen PITX2 RGQ PCR assay equivalent PMR data with PMRequiv = 12 are quite comparable and 
9 of 204 patients (4.4%) of the clinical validation group switch from the low-risk group into the high-risk group 
with applying PMRequiv = 12. In current standard-of-care, this would lead to treatment of these patients with 
anthracycline-based chemotherapy.
Discussion
The clinical relevance of the PITX2 DNA-methylation status in breast cancer has been described in several stud-
ies8,10–14,24. The precise role of PITX2 DNA-methylation in breast carcinogenesis remains not fully understood. 
One publication described a prognostic role of PITX2 DNA-methylation for the clinical course of breast cancer10. 
In the studies performed by Maier et al.11 and Harbeck et al.11,12, PITX2 DNA-methylation showed the strongest 
correlation with metastasis-free survival in node negative tamoxifen-treated breast cancer patients. The study 
PMR > 12. (f) Kaplan-Meier analysis for DFS of high-risk breast cancer patients treated with anthracycline-
based chemotherapy plus endocrine therapy (n = 96) using the optimized PITX2 cut-off point of PMRequiv = 12 
(HR 3.057; p = 0.002). Upper line: PMR ≤ 12. Lower line: PMR > 12. Kaplan-Meier analysis: n = 2 patients with 
DFS at 147 and 166 months were censored for DFS analysis with follow-up time of 120 months.
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of Maier et al., 2007 also showed good correlation of PITX2 DNA-methylation determined on a methylation 
specific oligonucleotide microarray and a research use only (RUO) qPCR assay11. These studies underline PITX2 
DNA-methylation as a potential biomarker for predicting outcome in patients with node negative breast cancer.
The role of DNA-methylation in clinical cancer research gained significant attention. DNA-methylation anal-
ysis comprises single gene analysis on simple endpoint PCR based approaches, quantitative methylation spe-
cific PCR and oligonucleotide microarrays25–27. Evidence has been accumulated that DNA-methylation based 
markers - depending of the method applied - can be predictive or prognostic for clinical outcome and might 
improve diagnosis and treatment28–31. Hartmann et al., 2009 showed for the first time the clinical relevance of 
PITX2 methylation status in ER positive, HER2 negative, lymph node positive breast cancer patients treated with 
anthracycline-based chemotherapy13. PITX2 hypermethylation was associated with high risk of recurrence in 
that patient cohort [HR 1.66, p = 0.002] and was also associated with poor DFS (HR 1.47, p = 0.0084)13. However, 
the transformation of a research-based assay into a fully analytically validated test system rarely occurred and, 
therefore, only a few examples transitioned into clinical routine setting.
Array-based methodologies often are better suitable for marker discovery studies, whereas, single marker 
based quantitative DNA-methylation based assays are more reliable, cost-effective, sensitive and robust for 
high-throughput analysis in diagnostic or clinical chemistry units.
Therefore, a real-time PCR-based PITX2 marker assay as RUO test was developed for verification studies 
of the PITX2 marker11,12. Harbeck et al., 2008 showed that this RUO qPCR-based test can be reliably used in 
high-throughput studies (n = 399). This PCR-based assay demonstrated high reproducibility in replicate meas-
urements (r ≥ 0.95, n = 150). Furthermore, Harbeck et al. (2008) showed, that PITX2 PMR values correlated 
between matched fresh frozen and FFPE tissue samples (n = 89, r = 0.81). Therefore, an expansion of the PITX2 
test for assessment of more easily available FFPE material was indicated. The authors also concluded that tumor 
heterogeneity does not impact the analysis of PMR (percent methylation ratio) values in FFPE tissue blocks12.
The present technical evaluation study was based on the development of the aforementioned Research Use 
Only (RUO) assay into a CE certified in vitro diagnostics (IVD) kit including optimization of the workflow and 
analytical and technical verification and validation of the assay for its use in routine diagnostics. The assay was 
also optimized for use of the more easily available FFPE material. For the therascreen PITX2 RGQ assay single-site 
and multi-site precision studies were performed according to CLSI guideline22 for technical certification of 
the assay, proving high robustness (average coefficient of variation (CV) at about 16%). Because the average 
Figure 3. Establishment of the transformation curve. Correlation of the PMRcalc (mathematically converted 
microarray data) and PMRexp (data determined by therascreen PITX2 RGQ PCR assay) with 121 samples (41 
ER−; 80 ER+). Coefficient factors: r-squared = 0.5219; r = 0.722.
Tumor Sample Mean Value PMR CV PMR CV (%) PMR range (absolute)
Tu 16.1–5 11.36 3.05 26.84 5.69–16.11
Tu 10.1–5 21.53 5.99 27.81 12.79–31.21
Tu 12.1–5 30.13 8.95 29.70 14.50–46.02
Tu 14.1–5 57.86 12.47 21.56 41.76–80.55
Tu 15.1–5 73.70 6.87 9.32 64.00–83.60
Tu 03.1–5 54.82 4.16 7.59 46.89–62.55
Table 4. Tumor heterogeneity of PITX2 DNA-methylation. Five consecutive tissue sections (Tu xx.1–5) of 
six tumor specimens Tu 16, 10, 12, 14, 15 and 3 were analyzed in duplicates for each tissue section and the 
mean PMR value, the coefficients of variation (CV) for PMR and in percent were determined. The PMR range 
represents the CV in absolute PMR values.
www.nature.com/scientificreports/
9Scientific REPORTS |         (2018) 8:16861  | DOI:10.1038/s41598-018-34919-1
coefficient of variation was determined to 16%, there is a grey area in absolute PMR values around the cut-off 
of PMR 12 between PMR 10 to 14. For patients with tumor PMR results of PITX2 DNA-methylation in this 
grey area, the physician would very likely take additional clinical parameters for a therapy recommendation into 
account. The overall sample pass rate of DNA extraction for qPCR analysis was 95%, e.g. samples yielded suffi-
cient DNA amounts for input into bisulfite conversion and overall 95% of all samples gave valid results according 
to the certified assay profile validity criteria18. These data emphasize that the therascreen PITX2 RGQ assay can 
reliably be used for analysis of FFPE-derived material. The amplifyable copy numbers assessed based on CT val-
ues of each sample did not correlate with the overall DNA yield, showing that DNA integrity in the original FFPE 
sample is critical on test outcome. Nevertheless, one 5 µm section with more than 100 mm2 tissue area is sufficient 
to achieve an overall success rate of more than 95% with the therascreen PITX2 qPCR workflow.
The present study confirms applying the analytically validated therascreen PITX2 RGQ PCR assay that PMR 
values derived from fresh-frozen tissue samples correlate (r = 0.722; r-squared = 0.5219; n = 121) with the 
microarray results from the Hartmann collective13. We could also demonstrate a statistically highly significant 
correlation between PITX2 DNA methylation (therascreen PITX2 RGQ PCR assay equivalent PMR data with 
PMRequiv = 12) and clinical outcome (DFS) for patients treated with anthracycline-based chemotherapy.
Predictive tests to avoid undertreatment or overtreatment of high-risk breast cancer patients are urgently 
needed. Therefore, a test which can predict outcome in patients receiving anthracycline-based chemotherapy is 
of high unmet medical need because it would improve the compliance of patients, who will most likely benefit, to 
stay on therapy despite potential toxic side effects. Vice versa patients who will most likely not benefit might be 
considered for an alternative treatment option.
The therascreen PITX2 RGQ PCR kit is now commercially available, and it is intended to be used by qualified 
users trained in molecular biology techniques and in in vitro diagnostic procedures. The therascreen PITX2 RGQ 
PCR kit with the determined cut-off value of PMR 12 will allow identification of high-risk, lymph node-positive, 
estrogen-receptor positive, HER2-negative breast cancer patients treated with anthracycline-based chemotherapy 
with good versus poor outcome. Future studies using independent cohort of ER+ breast cancer FFPE tissue sam-
ples and also prospective clinical trials are required to further substantiate the clinical cut-off of PMR 12. In con-
clusion, PITX2 DNA-methylation determined with the analytically validated therascreen PITX2 RGQ PCR assay 
may improve personalized breast cancer management and treatment decision in high-risk (lymph node-positive, 
estrogen-receptor positive, HER2-negative) breast cancer.
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